AUTHORS
Brianna Leigh Mitchell, Nydia C. Jaimes-Delgadillo2, Charles C. Chu, PhD3, Clive S. Zent, MD4, Michael R. Elliott, Associate Professor5
AFFILIATIONS
1 Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama, United States
2 Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, United States
3 Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, United States
4 Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, United States
5 Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama, United States
ABSTRACT
Monoclonal antibodies (mAbs) are widely used for the effective treatment of cancer, autoimmune disorders, and infectious diseases. However, initial mAb administration in treatment-naïve patients frequently triggers a rapid spike in circulating cytokines, termed cytokine release syndrome (CRS). In a subset of patients, CRS is associated with rapid onset of fever, hypotension, rash, chills, and dyspnea, collectively termed first-dose infusion reactions (FDIRs), which require clinical intervention, temporary cessation of treatment, and close supervision by trained medical staff. In chronic lymphocytic leukemia (CLL), initial mAb administration causes CRS in 64% of patients, 77% of whom develop FDIRs. Even at low doses, rituximab, an anti-CD20 mAb used to treat CLL, rapidly elevates inflammatory mediators (e.g. IL-6, IL-8, CXCL10). Despite this, the mechanisms of cytokine release following initial mAb therapy remain unknown.
Current findings show within minutes after anti-CD20 infusion, circulating B cells become opsonized by mAbs and are rapidly engulfed by resident macrophages in the liver and spleen via antibody-dependent cellular phagocytosis (ADCP), the key cytotoxic mechanism of anti-CD20 mAbs. This rapid onset of ADCP following initial anti-CD20 infusion correlates with CRS, highlighting ADCP by tissue-resident macrophages as a potential driver of anti-CD20-induced cytokine release. In preliminary studies, we found that human monocyte-derived macrophages (hMDMs) co-cultured with anti-CD20-opsonized CLL cells in vitro produced increased levels of IL-6, IL-8, and CXCL10 in cell culture supernatants compared to co-cultures without mAb. We extended these observations using a co-culture system in which M-CSF-differentiated hMDMs from healthy donors are co-cultured with Ramos B cells opsonized with anti-CD20 or anti-CD52 mAbs. Live-cell imaging confirmed rapid hMDM ADCP of mAb-opsonized Ramos cells over a four hour time course. Under these conditions, both anti-CD20 and anti-CD52 showed increased IL-6 and IL-8 in supernatants compared to controls, supporting a model in which CRS-related cytokine release is directly linked to macrophage ADCP.
To understand the broader impact of ADCP on mAb-induced CRS, we used a multiplex 13-plex bead-based cytokine panel to profile hMDM-Ramos co-cultures undergoing ADCP with anti-CD20 or anti-CD52 mAbs. In this system, mAb-mediated ADCP selectively increases the chemokines MCP-1/CCL2 and IL-8/CXCL8, while several other CRS-associated cytokines remain at or near baseline. These results highlight MCP-1 and IL-8 as main ADCP-responsive cytokines in this first-dose mAb model.
In ongoing studies, we are defining the specific ADCP pathways and phagocytosis events that drive cytokine release, focusing particularly on MCP-1 and IL-8. We will compare complement-dependent ADCP and Fc receptor-dependent ADCP via depletion and pharmacological approaches. In doing so, we aim to define to what extent mAb-induced MCP-1 and IL-8 production are linked to complement and Fc receptor-mediated ADCP. In parallel, we are also using cytochalasin D and bafilomycin A1 to separate antibody binding from internalization and phagosome acidification and degradation to determine which of these steps are required for cytokine release. Together, our ongoing studies will define the contribution of macrophage ADCP to cytokine release during initial mAb administration. These studies will improve our understanding of mAb-induced CRS and provide mechanistic insight needed to design strategies to make mAb therapies safer and more widely accessible while preserving their therapeutic efficacy.
DISCLOSURES
Brianna Leigh Mitchell: No relevant conflicts of interest to declare.